Personalized OncoGenomics (POG)
|Project Leaders||Janessa Laskin, Marco Marra|
|Project Co-Investigators||Daniel Renouf, Howard Lim, Steven Jones, Stephen Yip and others|
For all project related inquiries contact: POGinfo@bcgsc.ca
The BC Cancer Agency’s Personalized OncoGenomics (POG) program is a clinical research initiative that is embedding genomic sequencing into real-time treatment planning for BC patients with incurable cancers.
Cancer is a complex biological process. We categorize cancers according to their site of origin (e.g. lung, breast, liver, colon) as each one is different, but even within these groupings there are subtypes with differences in response to treatment and overall behaviour. The POG program is a collaborative research study including many BCCA oncologists, pathologists and other clinicians along with the Genome Sciences Centre (GSC), which aims to decode the genome – the entire DNA and RNA inside the cell – of each patient’s cancer, to understand what is enabling it to grow. Using this genomic data in clinical decision-making should allow us to develop treatment strategies to block its growth, identify clinical trials that the patient may benefit from and potentially identify less toxic and more effective therapeutic options.
Who is eligible for POG? This is a highly experimental research program for cancer patients being treated at the BC Cancer Agency (BC residents only) with metastatic disease, either before any chemotherapy or after one line of chemotherapy; there are some disease/type specific criteria that may also apply to individual cases. Currently the study can enroll 6-8 patients per week and thus they are a highly selected group. For more information on POG and eligibility, BC patients should speak to their medical oncologist. Ethical Review Board and other approvals in place for the study do not allow non-BC residents to be included in the study.
Who do I contact for more information on POG? For more information on POG and eligibility, BC patients should speak to their medical oncologist.
How do patients get enrolled in POG? BC patients should discuss their clinical treatment options, including clinical trials and POG, with their oncologist.
More information about the POG program is also available at ClinicalTrials.gov - Identifier: NCT02155621
If you would like to support POG, click here.
Recent POG publications:
- Sheffield, B. S. et al. Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. Curr Oncol 23, e571-e575, (2016) doi:10.3747/co.23.3165.
- Parker, J. D. et al. Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing. Cold Spring Harb Mol Case Stud 2, a000679, (2016) doi:10.1101/mcs.a000679.
- Laskin, J. et al. Clinicians identify high need to increase their genomic literacy to applied cancer genomics. Annals of Oncology 27, 1379P-1379P, (2016) doi:10.1093/annonc/mdw387.16.
- Jones, M. R. et al. Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 27, 801-806, doi:10.1093/annonc/mdw060 (2016).
POG in the news:
- Can a computer select the best cancer treatment? B.C. researchers to study whether Watson can move from winning Jeopardy to doing doctors’ legwork – Vancouver Sun, July 2, 2015
- IBM Collaborates with 14 Cancer Institutes to Decipher Genomic Data – GenomeWeb, May 5, 2015
- With New Funds, BC Cancer Agency Aims to Sequence 300 Patients for Personalized Onco-Genomics Trial – GenomeWeb, March 13, 2015
- Blood pressure drug shrinks cancer in ‘miracle’ clinical trial – CTV News Vancouver, March 9, 2015
MYSTERY REVEALED: identity of the high profile, Vancouver biomedical mogul, 1st in world to get gene sequencing for cancer Rx - Vancouver Sun, November 1, 2014
For all project related inquiries please contact: POGinfo@bcgsc.ca